News and Announcements
Human trials begin in Brisbane, Melbourne for treatment of deadly brain tumours
- Published November 26, 2014 9:51AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Source: ABC News; Published: Tuesday, 25th November 2014
A world-first human trial set to begin in Brisbane and Melbourne has the potential to be one of the biggest breakthroughs in the treatment of brain cancer, researchers say.
Scientists are confident an antibody created to prolong the lives of people suffering from almost-always fatal Glioblastoma tumour may even offer a cure.
As part of the trial, 20 patients with the recurrent brain tumour will be treated at the Royal Brisbane and Women’s Hospital and the Austin Hospital in Melbourne with the antibody that specifically targets a cancer protein on the surface of the tumour cells.
QIMR Berghofer Medical Research Institute’s professor Andrew Boyd discovered that cancer protein, EphA3, more than 20 years ago.
He also developed the antibody that has been shown to specifically target cancer cells which express EphA3.
To read the full article please click here.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
